半枝莲联合反应停治疗肝癌的实验研究

Experimental Study on Combination of Intratumor Scutellaria Barbata Injection and Thalidomide on Liver Cancer

目的通过BALB/C小鼠皮下接种肝癌H22细胞建立移植瘤模型,采用半枝莲乙醇提取液瘤内注射联合反应停治疗小鼠肝癌,探讨两药联合对肝癌移植瘤的抑制作用。方法体外培养小鼠肝癌H22细胞,取对数生长期细胞试验。乙醇回流提取半枝莲。接种H22细胞于BALB/C小鼠皮下建立肝癌H22的移植瘤模型。28只雄性BALB/C小鼠随机分为4组,每组7只。A组:反应停灌胃;B组:半枝莲乙醇提取液瘤内注射;C组:半枝莲乙醇提取液、反应停联合用药;D组:1%乙醇0.2～0.5mL瘤内注射。观察肿瘤大小和瘤重,比较抑瘤效果。移植瘤采用抗CD31单抗做免疫组化染色,测定移植瘤组织微血管密度(MVD)。结果A、C组之间瘤重差异有统计学意义(P<0.01),B、C组之间差异有统计学意义(P<0.05)。A、B、C组抑瘤率分别为18.11%、53.15%和71.65%;协同系数0.74。3个治疗对照组之间微血管计数比较差异有统计学意义(P<0.01),SNK-q检验显示A组和B组之间差异不明显(P>0.05),A、B组分别与C组比较差异有统计学意义。结论半枝莲乙醇提取液瘤内注射联合应用反应停对小鼠H22肝癌移植瘤有较强的抑制作用。半枝莲和反应停均有抗血管生成作用,两药联用对肿瘤微血管生成的抑制有协同作用。

Objective BALB/C mice were inoculated subcutaneously with hepatoma 22 （H22） cells, and the treatment effect of thalidomide and intratumor injection of ethanol extract of Scutellaria Barbata （SB） on tumor growth were evaluated. Methods In vitro, mouse H22 liver cells were cultivated, and H22 cells in the logarithmic growth phase were tested. SB was extracted in the ethanol recirculation. A total of 28 BALB/C male mice inoculated subcutaneously with H22 cells were randomly divided into 4 groups, 7 mice per group. Group A： intragastric administration with thalidomide. Group B： SB intratumor injection. Group C： combination of thalidomide and SB with the same administration as Group A and Group B. Group D （control group）： 1% Ethanol 0.2-0.5 mL intratumor injection. Tumor volumes of four groups were observed and the tumors were weighed. The microvessel densities （MVD） of all transplantation tumors were measured by immunohistochemical staining with anti-CD31 monoclonal antibody. Results There were statistically significant differences between Group C and Group A （P〈0.01）, or Group B （P〈0.05）. The cooperative coefficient was 0.74, meanwhile the inhibititory rates of Group A, B and C were 18.11%, 53.15% and 71.65%, respectively. Measurement of Microvessel Count： There were Statistically significant differences among the treated groups and the control group D （P〈0.01）, no statistically significant differences between group A and B （P 〉0.05）. The studies showed statistically differences between Group C and Group A （P〈0.05）, and between Group C and Group B （P〈0.01）, respectively. Conclusions The combinatation of intratumor SB injection and thalidomide elicited significant antitumor activities on the transplanted tumor model of H22. Anti-angiogenesis effects of SB and thalidomide was found, furthermore, the combination agent showed synergistic action of antiangiogenesis.